Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina
Background: little information is available on the effect of pegylated interferon (PEG) and ribavirin (RBV) in patients with chronic hepatitis due to virus C (CHC) who were non-responders to previous treatment. Objectives: to evaluate response to treatment in patients who were non-responders to prev...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aran Ediciones
2005-05-01
|
| Series: | Revista Espanola de Enfermedades Digestivas |
| Subjects: | |
| Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082005000500002 |
| _version_ | 1819294677850914816 |
|---|---|
| author | F. Carnicer P. Zapater A. Gutiérrez A. García F. Ruiz M. López |
| author_facet | F. Carnicer P. Zapater A. Gutiérrez A. García F. Ruiz M. López |
| author_sort | F. Carnicer |
| collection | DOAJ |
| description | Background: little information is available on the effect of pegylated interferon (PEG) and ribavirin (RBV) in patients with chronic hepatitis due to virus C (CHC) who were non-responders to previous treatment. Objectives: to evaluate response to treatment in patients who were non-responders to previous treatment. Methods: one hundred and twenty-four patients who were non-responders to previous treatment were included. All patients were treated with PEG alpha 2b interferon (dose: 1.5 mg/kg body weight) and RBV (weight-dependent dosage). A qualitative PCR of virus C after six months was evaluated. In those in whom this was positive, treatment was discontinued; in those who were negative treatment was continued to the end of the year. Results: response following treatment (RFT) was 35.4% (44 patients), and sustained viral response (SVR) 29.8% (37 patients). No relation was observed between RFT, SVR and any previous treatment. RFT was dependent on low initial viremia and SVR was significantly and independently related to low serum hepatitis C RNA and a non-1 genotype. In general, treatment was well tolerated. Medication was discontinued in 5 patients, and doses reduced in 18. Conclusion: on retreatment with PEG and RBV a SVR of 29.8% was achieved in patients who had not responded to previous treatment, so its use in this group of patients is indicated.<br>Introducción: existe poca información del resultado del tratamiento con interferón pegilado (PEG) y ribavirina (RBV) en enfermos con hepatitis crónica por virus C (HCC) no respondedores a tratamientos previos. Objetivos: valorar la respuesta al tratamiento en enfermos no respondedores a tratamientos anteriores. Métodos: se incluyeron 124 enfermos no respondedores a tratamientos previos. Todos los pacientes fueron tratados con PEG interferón alfa 2b (dosis: 1,5 mg/kg peso) y RBV (dosis ajustada al peso). Se valoró la PCR cualitativa del virus C al 6º mes. A los que la presentaban positiva se suspendió el tratamiento, mientras en los que era negativa se continuó el mismo hasta finalizar un año. Resultados: la respuesta al final de tratamiento (RFT) fue del 35,4% (44 enfermos) y la respuesta viral sostenida (RVS) del 29,8% (37 enfermos). No se observó que existiera relación alguna entre la RFT y la RVS con el tratamiento previo. La RFT fue dependiente de la existencia de una viremia baja al inicio del tratamiento y la RVS se relacionó de forma significativa e independiente con una viremia baja y un genotipo distinto al 1. El tratamiento fue bien tolerado en general. Se suspendió la medicación en 5 enfermos y se redujo la dosis en 18. Conclusión: el retratamiento con PEG y RBV consigue una RVS del 29,8% de los enfermos no respondedores a tratamientos previos, por lo que estaría indicado su uso en este grupo de enfermos. |
| first_indexed | 2024-12-24T04:30:08Z |
| format | Article |
| id | doaj.art-d1084f82e68342989a1e2b04081277e8 |
| institution | Directory Open Access Journal |
| issn | 1130-0108 |
| language | English |
| last_indexed | 2024-12-24T04:30:08Z |
| publishDate | 2005-05-01 |
| publisher | Aran Ediciones |
| record_format | Article |
| series | Revista Espanola de Enfermedades Digestivas |
| spelling | doaj.art-d1084f82e68342989a1e2b04081277e82022-12-21T17:15:28ZengAran EdicionesRevista Espanola de Enfermedades Digestivas1130-01082005-05-01975306316Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirinaF. CarnicerP. ZapaterA. GutiérrezA. GarcíaF. RuizM. LópezBackground: little information is available on the effect of pegylated interferon (PEG) and ribavirin (RBV) in patients with chronic hepatitis due to virus C (CHC) who were non-responders to previous treatment. Objectives: to evaluate response to treatment in patients who were non-responders to previous treatment. Methods: one hundred and twenty-four patients who were non-responders to previous treatment were included. All patients were treated with PEG alpha 2b interferon (dose: 1.5 mg/kg body weight) and RBV (weight-dependent dosage). A qualitative PCR of virus C after six months was evaluated. In those in whom this was positive, treatment was discontinued; in those who were negative treatment was continued to the end of the year. Results: response following treatment (RFT) was 35.4% (44 patients), and sustained viral response (SVR) 29.8% (37 patients). No relation was observed between RFT, SVR and any previous treatment. RFT was dependent on low initial viremia and SVR was significantly and independently related to low serum hepatitis C RNA and a non-1 genotype. In general, treatment was well tolerated. Medication was discontinued in 5 patients, and doses reduced in 18. Conclusion: on retreatment with PEG and RBV a SVR of 29.8% was achieved in patients who had not responded to previous treatment, so its use in this group of patients is indicated.<br>Introducción: existe poca información del resultado del tratamiento con interferón pegilado (PEG) y ribavirina (RBV) en enfermos con hepatitis crónica por virus C (HCC) no respondedores a tratamientos previos. Objetivos: valorar la respuesta al tratamiento en enfermos no respondedores a tratamientos anteriores. Métodos: se incluyeron 124 enfermos no respondedores a tratamientos previos. Todos los pacientes fueron tratados con PEG interferón alfa 2b (dosis: 1,5 mg/kg peso) y RBV (dosis ajustada al peso). Se valoró la PCR cualitativa del virus C al 6º mes. A los que la presentaban positiva se suspendió el tratamiento, mientras en los que era negativa se continuó el mismo hasta finalizar un año. Resultados: la respuesta al final de tratamiento (RFT) fue del 35,4% (44 enfermos) y la respuesta viral sostenida (RVS) del 29,8% (37 enfermos). No se observó que existiera relación alguna entre la RFT y la RVS con el tratamiento previo. La RFT fue dependiente de la existencia de una viremia baja al inicio del tratamiento y la RVS se relacionó de forma significativa e independiente con una viremia baja y un genotipo distinto al 1. El tratamiento fue bien tolerado en general. Se suspendió la medicación en 5 enfermos y se redujo la dosis en 18. Conclusión: el retratamiento con PEG y RBV consigue una RVS del 29,8% de los enfermos no respondedores a tratamientos previos, por lo que estaría indicado su uso en este grupo de enfermos.http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082005000500002TratamientoPeginterferónribavirinaNo respondedoresHepatitis CTreatmentPeginterferonribavarinUnresponsive to treatmentHepatitis C |
| spellingShingle | F. Carnicer P. Zapater A. Gutiérrez A. García F. Ruiz M. López Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina Revista Espanola de Enfermedades Digestivas Tratamiento Peginterferón ribavirina No respondedores Hepatitis C Treatment Peginterferon ribavarin Unresponsive to treatment Hepatitis C |
| title | Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina |
| title_full | Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina |
| title_fullStr | Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina |
| title_full_unstemmed | Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina |
| title_short | Treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin Tratamiento con PEG interferón alfa 2b y ribavirina en enfermos previamente tratados con interferón estándar en monoterapia o combinado con ribavirina |
| title_sort | treatment with pegylated interferon alpha 2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin tratamiento con peg interferon alfa 2b y ribavirina en enfermos previamente tratados con interferon estandar en monoterapia o combinado con ribavirina |
| topic | Tratamiento Peginterferón ribavirina No respondedores Hepatitis C Treatment Peginterferon ribavarin Unresponsive to treatment Hepatitis C |
| url | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082005000500002 |
| work_keys_str_mv | AT fcarnicer treatmentwithpegylatedinterferonalpha2bandribavirininpatientsunresponsivetoprevioustreatmentswithstandardinterferonasmonotherapyorcombinedwithribavirintratamientoconpeginterferonalfa2byribavirinaenenfermospreviamentetratadosconinterferonestandarenmonotera AT pzapater treatmentwithpegylatedinterferonalpha2bandribavirininpatientsunresponsivetoprevioustreatmentswithstandardinterferonasmonotherapyorcombinedwithribavirintratamientoconpeginterferonalfa2byribavirinaenenfermospreviamentetratadosconinterferonestandarenmonotera AT agutierrez treatmentwithpegylatedinterferonalpha2bandribavirininpatientsunresponsivetoprevioustreatmentswithstandardinterferonasmonotherapyorcombinedwithribavirintratamientoconpeginterferonalfa2byribavirinaenenfermospreviamentetratadosconinterferonestandarenmonotera AT agarcia treatmentwithpegylatedinterferonalpha2bandribavirininpatientsunresponsivetoprevioustreatmentswithstandardinterferonasmonotherapyorcombinedwithribavirintratamientoconpeginterferonalfa2byribavirinaenenfermospreviamentetratadosconinterferonestandarenmonotera AT fruiz treatmentwithpegylatedinterferonalpha2bandribavirininpatientsunresponsivetoprevioustreatmentswithstandardinterferonasmonotherapyorcombinedwithribavirintratamientoconpeginterferonalfa2byribavirinaenenfermospreviamentetratadosconinterferonestandarenmonotera AT mlopez treatmentwithpegylatedinterferonalpha2bandribavirininpatientsunresponsivetoprevioustreatmentswithstandardinterferonasmonotherapyorcombinedwithribavirintratamientoconpeginterferonalfa2byribavirinaenenfermospreviamentetratadosconinterferonestandarenmonotera |